Collegium Pharma (COLL) Tops Q2 EPS by $1.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts COLL Hot Sheet
Join SI Premium – FREE
Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.79, $1.43 better than the analyst estimate of $0.36. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $84.77 million.
For earnings history and earnings-related data on Collegium Pharma (COLL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
